Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

Bibliographic Details
Main Authors:	Reyes-Sandoval, A, Sridhar, S, Berthoud, T, Moore, A, Harty, J, Gilbert, S, Gao, G, Ertl, H, Wilson, J, Hill, A
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
by: Reyes-Sandoval, A, et al.
Published: (2008)

Immunogenicity of a pre-erythrocytic-stage malaria insert ME-trap encoded by novel simian adenoviral vectors
by: Reyes-Sandoval, A, et al.
Published: (2005)

Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.
by: Sridhar, S, et al.
Published: (2008)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
by: Folegatti, PM, et al.
Published: (2019)

NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS
by: Goodman, A, et al.
Published: (2009)

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
by: Fitzgerald, J, et al.
Published: (2003)

In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector
by: Reka Lorincz, et al.
Published: (2023-02-01)

EVALUATION OF SIMIAN ADENOVIRAL VECTOR ADCH63 EXPRESSING MSP-1 AS A CANDIDATE BLOOD-STAGE MALARIA VACCINE
by: Goodman, A, et al.
Published: (2009)

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines
by: Eriko Padron-Regalado, et al.
Published: (2022-08-01)

Immunogenicity and cross-reactivity of rhesus adenoviral vectors
by: Iampietro, M, et al.
Published: (2018)

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
by: Reyes-Sandoval, A, et al.
Published: (2004)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
by: Dicks, M, et al.
Published: (2011)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
by: Xiang, Z, et al.
Published: (2003)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
by: Reyes-Sandoval, A, et al.
Published: (2011)

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
by: Goodman, A, et al.
Published: (2010)

Simian adenoviruses as vaccine vectors
by: Morris, S, et al.
Published: (2016)

Simian adenoviruses as vaccine vectors
by: Morris, S, et al.
Published: (2016)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
by: Capone, S, et al.
Published: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
by: Capone, S, et al.
Published: (2010)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
by: Reyes-Sandoval, A, et al.
Published: (2011)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
by: Ewer (nee Russell), K, et al.
Published: (2017)

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
by: Florian Kreppel, et al.
Published: (2021-02-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Folegatti, P, et al.
Published: (2019)

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes
by: von Delft, A, et al.
Published: (2017)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
by: Antrobus, R, et al.
Published: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
by: Antrobus, R, et al.
Published: (2014)

New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1, (vol 78, pg 4610, 2010)
by: Goodman, A, et al.
Published: (2011)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
by: Katie Ewer, et al.
Published: (2017-12-01)

Progression of Plasmodium berghei through Anopheles stephensi is density-dependent.
by: Sinden, R, et al.
Published: (2007)

Progression of Plasmodium berghei through Anopheles stephensi is density-dependent
by: Sinden, R, et al.
Published: (2007)

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
by: Lynda Coughlan
Published: (2020-05-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Pedro M. Folegatti, et al.
Published: (2019-05-01)

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
by: Vuola, J, et al.
Published: (2005)

Adenoviral vectors as novel vaccines for influenza.
by: Coughlan, L, et al.
Published: (2015)

Progression of Plasmodium berghei through Anopheles stephensi is density-dependent.
by: Robert E Sinden, et al.
Published: (2007-12-01)

Erratum: Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier (Journal of Virology (2003) 77:20 (10780-10789)
by: Xiang, Z, et al.
Published: (2005)

Maintenance of the Plasmodium berghei life cycle.
by: Sinden, R, et al.
Published: (2002)

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
by: Goodman, A, et al.
Published: (2013)

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.
by: Tatsis, N, et al.
Published: (2007)